The evolution of imaging in cancer: Current state and future challenges

Seminars in Oncology

Volumn 38, Issue 1, 2011, Pages 3-15

  Higgins, Luke J ^a   Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BROMINE 76; CAPROMAB PENDETIDE IN 111; CARBON 13; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; FLUORESCENT DYE; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLSPIPERONE F 18; FLUOROURACIL; IMATINIB; INDIUM 111; IODINE 124; IODINE 131; METHIONINE C 11; MONOCLONAL ANTIBODY J591; PENTETREOTIDE IN 111; PHOSPHORUS 31; PROSTATE SPECIFIC ANTIGEN; PROTEIN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SUPERPARAMAGNETIC IRON OXIDE; TANESPIMYCIN; TECHNETIUM 99M; TRASTUZUMAB; TRASTUZUMAB F(AB')2 FRAGMENT GA 68; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 86; ZIRCONIUM 89;

APPARENT DIFFUSION COEFFICIENT MAPPING; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER THERAPY; CELL METABOLISM; CELL MIGRATION; CELL SPECIFICITY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION COEFFICIENT; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; FLUORESCENCE IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IN VIVO STUDY; METABOLIC DISORDER; MOLECULAR IMAGING; NEAR INFRARED SPECTROSCOPY; NEOPLASM; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL TOMOGRAPHY; PERFUSION WEIGHTED IMAGING; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN INTERACTION; RADIOIMMUNOTHERAPY; RAMAN SPECTROMETRY; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GENE; ULTRASOUND; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION PROFILING; GENE THERAPY; HUMANS; MALE; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROSTATIC NEOPLASMS; TRANSLATIONAL RESEARCH;

EID: 79952176166     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.11.010     Document Type: Article

References (120)

1. S. Ogawa, T.M. Lee, A.R. Kay, and D.W. Tank Brain magnetic resonance imaging with contrast dependent on blood oxygenation Proc Natl Acad Sci U S A 87 1990 9868 9872 (Pubitemid 120016545)
2. D.M. Patterson, A.R. Padhani, and D.J. Collins Technology insight: water diffusion MRIa potential new biomarker of response to cancer therapy Nat Clin Pract Oncol 5 2008 220 233 (Pubitemid 351493681)
3. K.C. Lee, D.A. Bradley, and M. Hussain A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone Neoplasia 9 2007 1003 1011 (Pubitemid 350255347)
4. T.C. Kwee, T. Takahara, D.W. Klomp, and P.R. Luijten Cancer imaging: novel concepts in clinical magnetic resonance imaging J Intern Med 268 2010 120 132
5. Kovacs A, Toth L, Glavak C, et al. Integrating functional MRI information into radiotherapy planning of CNS tumorsearly experiences. Pathol Oncol Res. Epub ahead of print 2010 September 17.
6. W.H. Ng, K. Mukhida, and J.T. Rutka Image guidance and neuromonitoring in neurosurgery Childs Nerv Syst 26 2010 491 502
7. B.A. Moffat, T.L. Chenevert, and T.S. Lawrence Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response Proc Natl Acad Sci U S A 102 2005 5524 5529 (Pubitemid 40530291)
8. L. Mechtler Neuroimaging in neuro-oncology Neurol Clin 27 2009 171 201
9. D.A. Hamstra, T.L. Chenevert, and B.A. Moffat Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma Proc Natl Acad Sci U S A 102 2005 16759 16764 (Pubitemid 41688850)
10. R.N. Sawlani, J. Raizer, and S.W. Horowitz Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imagingpilot study Radiology 255 2010 622 628
11. G. Honey, and E. Bullmore Human pharmacological MRI Trends Pharmacol Sci 25 2004 366 374 (Pubitemid 38829490)
12. D.A. Mankoff A definition of molecular imaging J Nucl Med 48 2007 18N 21N
13. M.W. Johns, J.H. Gregson, G.C. Foster, C.H. Jaimet, and H.G. Thode Radioiodine 131 in the diagnosis of thyroid function Can Med Assoc J 68 1953 132 137
14. L. Sokoloff The deoxyglucose method: theory and practice Eur Neurol 20 1981 137 145 (Pubitemid 11087738)
15. E.J. Hoffman, M.E. Phelps, G. Wisenberg, H.R. Schelbert, and D.E. Kuhl Electrocardiographic gating in positron emission computed tomography J Comput Assist Tomogr 3 1979 733 739 (Pubitemid 10194604)
16. M.E. Phelps, J.C. Mazziotta, and S.C. Huang Study of cerebral function with positron computed tomography J Cereb Blood Flow Metab 2 1982 113 162 (Pubitemid 12024650)
17. R. Weissleder Molecular imaging in cancer Science 312 2006 1168 1171 (Pubitemid 43801133)
18. E.D. Agdeppa, and M.E. Spilker A review of imaging agent development AAPS J 11 2009 286 299
19. C.J. Anderson, J.W. Bulte, and K. Chen Design of targeted cardiovascular molecular imaging probes J Nucl Med 51 Suppl 1 2010 3S 17S
20. C.A. Boswell, and M.W. Brechbiel Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view Nucl Med Biol 34 2007 757 778 (Pubitemid 47503817)
21. A.N. Eberle, and G. Mild Receptor-mediated tumor targeting with radiopeptides Part 1. General principles and methods J Recept Signal Transduct Res 29 2009 1 37
22. W.C. Eckelman, R.C. Reba, and R.E. Gibson Receptor-binding radiotracers: a class of potential radiopharmaceuticals J Nucl Med 20 1979 350 357 (Pubitemid 9154089)
23. A. Chakrabarti, K. Zhang, and M.R. Aruva Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [(64)Cu]DO3A-peptide nucleic acid-peptide nanoparticles Cancer Biol Ther 6 2007 948 956 (Pubitemid 351574987)
24. R. Garcia Boy, E.M. Knapp, M. Eisenhut, U. Haberkorn, and W. Mier Enzymes/transporters Handb Exp Pharmacol 185 2008 131 143
25. J. Capala, and K. Bouchelouche Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy Curr Opin Oncol 22 2010 559 566
26. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480 (Pubitemid 34879334)
27. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis J Nucl Med 51 2010 543 550
28. T.H. Oude Munnink, W.B. Nagengast, and A.H. Brouwers Molecular imaging of breast cancer Breast 18 Suppl 3 2009 S66 S73
29. P.M. Smith-Jones, D.B. Solit, T. Akhurst, F. Afroze, N. Rosen, and S.M. Larson Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors Nat Biotechnol 22 2004 701 706 (Pubitemid 38702826)
30. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 2003 566 580 (Pubitemid 37361748)
31. M. Rudin, and R. Weissleder Molecular imaging in drug discovery and development Nat Rev Drug Discov 2 2003 123 131 (Pubitemid 37361644)
32. M. Rudin Noninvasive structural, functional, and molecular imaging in drug development Curr Opin Chem Biol 13 2009 360 371
33. M.G. Pomper, and J.S. Lee Small animal imaging in drug development Curr Pharm Des 11 2005 3247 3272 (Pubitemid 41300775)
34. M. Rudin, M. Rausch, and M. Stoeckli Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods Mol Imaging Biol 7 2005 5 13 (Pubitemid 41348870)
35. T.F. Massoud, and S.S. Gambhir Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes Dev 17 2003 545 580 (Pubitemid 36307540)
36. D.J. Kwekkeboom, B.L. Kam, and M. van Essen Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors Endocr Relat Cancer 17 2010 R53 R73
37. W.B. Edwards, B. Xu, and W. Akers Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor Bioconjug Chem 19 2008 192 200 (Pubitemid 351213851)
38. D.R. Elias, D.L. Thorek, A.K. Chen, J. Czupryna, and A. Tsourkas In vivo imaging of cancer biomarkers using activatable molecular probes Cancer Biomark 4 2008 287 305
39. H. Nomura, H. Sato, M. Seiki, M. Mai, and Y. Okada Expression of membrane-type matrix metalloproteinase in human gastric carcinomas Cancer Res 55 1995 3263 3266
40. Z.Y. Wu, J.H. Li, W.H. Zhan, and Y.L. He Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma World J Gastroenterol 12 2006 2941 2944
41. T. Koshiba, R. Hosotani, and M. Wada Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma Cancer 82 1998 642 650 (Pubitemid 28090274)
42. M. Zhou, and I. Ghosh Quantum dots and peptides: a bright future together Biopolymers 88 2007 325 339
43. J.V. Frangioni In vivo near-infrared fluorescence imaging Curr Opin Chem Biol 7 2003 626 634 (Pubitemid 37315800)
44. W.R. Algar, A.J. Tavares, and U.J. Krull Beyond labels: a review of the application of quantum dots as integrated components of assays, bioprobes, and biosensors utilizing optical transduction Anal Chim Acta 673 2010 1 25
45. R. Paulmurugan, and S.S. Gambhir Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation Anal Chem 75 2003 1584 1589 (Pubitemid 36512595)
46. R. Paulmurugan, Y. Umezawa, and S.S. Gambhir Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies Proc Natl Acad Sci U S A 99 2002 15608 15613 (Pubitemid 35407485)
47. G. Vande Velde, V. Baekelandt, T. Dresselaers, and U. Himmelreich Magnetic resonance imaging and spectroscopy methods for molecular imaging Q J Nucl Med Mol Imaging 53 2009 565 585
48. I. Rodriguez, S. Perez-Rial, and J. Gonzalez-Jimenez Magnetic resonance methods and applications in pharmaceutical research J Pharm Sci 97 2008 3637 3665
49. R.G. Blasberg, and J.G. Tjuvajev Molecular-genetic imaging: current and future perspectives J Clin Invest 111 2003 1620 1629 (Pubitemid 38057741)
50. C.H. Contag, and M.H. Bachmann Advances in in vivo bioluminescence imaging of gene expression Annu Rev Biomed Eng 4 2002 235 260 (Pubitemid 35217421)
51. A. Jacobs, J.G. Tjuvajev, and M. Dubrovin Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo Cancer Res 61 2001 2983 2995 (Pubitemid 32691944)
52. A. Jacobs, J. Voges, R. Reszka, M. Lercher, A. Gossmann, and L. Kracht Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas Lancet 358 2001 727 729 (Pubitemid 32823405)
53. D.C. MacLaren, S.S. Gambhir, and N. Satyamurthy Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals Gene Ther 6 1999 785 791 (Pubitemid 29243651)
54. D.X. Fu, Y. Tanhehco, and J. Chen Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors Nat Med 14 2008 1118 1122
55. C.Y. Zhang, J. Lu, and A. Tsourkas Iron chelator-based amplification strategy for improved targeting of transferrin receptor with SPIO Cancer Biol Ther 7 2008 889 895
56. A.A. Gilad, M.T. McMahon, and P. Walczak Artificial reporter gene providing MRI contrast based on proton exchange Nat Biotechnol 25 2007 217 219 (Pubitemid 46227121)
57. F. Kiessling Noninvasive cell tracking Handb Exp Pharmacol 2008 305 321
58. M. Srinivas, E.H. Aarntzen, and J.W. Bulte Imaging of cellular therapies Adv Drug Deliv Rev 62 2010 1080 1093
59. 18F]FHBG Nat Protoc 1 2006 3069 3075
60. I.J. de Vries, W.J. Lesterhuis, and J.O. Barentsz Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy Nat Biotechnol 23 2005 1407 1413 (Pubitemid 41679393)
61. 18F-FHBG PET in a patient with glioma Nat Clin Pract Oncol 6 2009 53 58
62. A.J. Atkinson, W.A. Colburn, V.G. DeGruttola, D.L. DeMets, G.J. Downing, and D.F. Hoth Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95 (Pubitemid 32225406)
63. D. Sarker, and P. Workman Pharmacodynamic biomarkers for molecular cancer therapeutics Adv Cancer Res 96 2007 213 268
64. P. Workman, E.O. Aboagye, and Y.L. Chung Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies J Natl Cancer Inst 98 2006 580 598 (Pubitemid 43904842)
65. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma Cancer Res 57 1997 3415 3423 (Pubitemid 27355486)
66. D.A. Mankoff, A.F. Shields, and K.A. Krohn PET imaging of cellular proliferation Radiol Clin North Am 43 2005 153 167 (Pubitemid 40326566)
67. 2 J Cereb Blood Flow Metab 7 1987 709 719 (Pubitemid 18029812)
68. R. Philipp The use of problem-management questionnaires in environmental medicine Public Health 106 1992 481 482
69. 11C-methionine PET of acute myocardial infarction J Nucl Med 50 2009 1283 1287
70. N. Gupta, P.M. Price, and E.O. Aboagye PET for in vivo pharmacokinetic and pharmacodynamic measurements Eur J Cancer 38 2002 2094 2107 (Pubitemid 35223247)
71. A.D. Nunn Molecular imaging and personalized medicine: an uncertain future Cancer Biother Radiopharm 22 2007 722 739
72. V. Tolmachev Imaging of HER-2 overexpression in tumors for guiding therapy Curr Pharm Des 14 2008 2999 3019
73. J. Zhou, J.O. Blakeley, and J. Hua Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging Magn Reson Med 60 2008 842 849
74. A. Zaheer, S.Y. Cho, and M.G. Pomper New agents and techniques for imaging prostate cancer J Nucl Med 50 2009 1387 1390
75. G.L. Wright, B.M. Grob, and C. Haley Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 48 1996 326 334 (Pubitemid 26279634)
76. W.R. Fair, R.S. Israeli, and W.D. Heston Prostate-specific membrane antigen Prostate 32 1997 140 148 (Pubitemid 27280358)
77. S. Perner, M.D. Hofer, and R. Kim Prostate-specific membrane antigen expression as a predictor of prostate cancer progression Hum Pathol 38 2007 696 701 (Pubitemid 46560805)
78. J.K. Troyer, M.L. Beckett, and G.L. Wright Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line Prostate 30 1997 232 242 (Pubitemid 27172834)
79. V. Nargund, D. Al Hashmi, and P. Kumar Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging BJU Int 95 2005 1232 1236 (Pubitemid 40799436)
80. 90Y radioimmunotherapy J Nucl Med 49 2008 1066 1074 (Pubitemid 351948014)
81. S.T. Tagawa, H. Beltran, and S. Vallabhajosula Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer Cancer 116 2010 1075 1083
82. 64Cu-labeled antibodies against native cell-adherent PSMA Prostate 70 2010 1413 1421
83. C.A. Foss, R.C. Mease, and H. Fan Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer Clin Cancer Res 11 2005 4022 4028 (Pubitemid 40791565)
84. 18F]DCFBC: a new imaging probe for prostate cancer Clin Cancer Res 14 2008 3036 3043
85. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer J Med Chem 53 2010 5333 5341
86. S.M. Hillier, K.P. Maresca, and F.J. Femia Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer Cancer Res 69 2009 6932 6940
87. S.A. Kularatne, Z. Zhou, J. Yang, C.B. Post, and P.S. Low Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents Mol Pharm 6 2009 790 800
88. 18F- labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer J Nucl Med 50 2009 2042 2048
89. 18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer J Nucl Med 48 2007 46 55 (Pubitemid 47555375)
90. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma J Nucl Med 48 2007 56 63 (Pubitemid 47555376)
91. A.B. Jani, T.H. Fox, D. Whitaker, and D.M. Schuster Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design Clin Nucl Med 34 2009 279 284
92. F. Dehdashti, J. Picus, and J.M. Michalski Positron tomographic assessment of androgen receptors in prostatic carcinoma Eur J Nucl Med Mol Imaging 32 2005 344 350 (Pubitemid 40562127)
93. M. Beheshti, W. Langsteger, and I. Fogelman Prostate cancer: role of SPECT and PET in imaging bone metastases Semin Nucl Med 39 2009 396 407
94. J.H. Kang, and J.K. Chung Molecular-genetic imaging based on reporter gene expression J Nucl Med 49 Suppl 2 2008 164S 179S
95. I. Serganova, P. Mayer-Kukuck, R. Huang, and R. Blasberg Molecular imaging: reporter gene imaging Handb Exp Pharmacol 2008 167 223
96. W.P. Deng, C.C. Wu, and C.C. Lee Serial in vivo imaging of the lung metastases model and gene therapy using HSV1-tk and ganciclovir J Nucl Med 47 2006 877 884
97. 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer J Nucl Med 47 2006 1161 1171
98. S.S. Gambhir, E. Bauer, and M.E. Black A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography Proc Natl Acad Sci U S A 97 2000 2785 2790 (Pubitemid 30159249)
99. M. Hingorani, C. Spitzweg, and G. Vassaux The biology of the sodium iodide symporter and its potential for targeted gene delivery Curr Cancer Drug Targets 10 2010 242 267
100. K.N. Barton, H. Stricker, and S.L. Brown Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate Mol Ther 16 2008 1761 1769
101. P. Ray, R. Tsien, and S.S. Gambhir Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects Cancer Res 67 2007 3085 3093 (Pubitemid 46724845)
102. C.M. Long, H.W. van Laarhoven, J.W. Bulte, and H.I. Levitsky Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes Cancer Res 69 2009 3180 3187
103. M. Djulbegovic, R.J. Beyth, and M.M. Neuberger Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials BMJ 341 2010 c4543
104. S.L. Deutscher Phage display in molecular imaging and diagnosis of cancer Chem Rev 110 2010 3196 3211
105. K.A. Kelly, S.R. Setlur, and R. Ross Detection of early prostate cancer using a hepsin-targeted imaging agent Cancer Res 68 2008 2286 2291 (Pubitemid 351521802)
106. Y. Tajima, M. Murakami, and K. Yamazaki Sentinel node mapping guided by indocyanine green fluorescence imaging during laparoscopic surgery in gastric cancer Ann Surg Oncol 17 2010 1787 1793
107. M. Noguchi, M. Yokoi, and Y. Nakano Axillary reverse mapping with indocyanine fluorescence imaging in patients with breast cancer J Surg Oncol 101 2010 217 221
108. H. Uhara, M. Takata, and T. Saida Sentinel lymph node biopsy in Japan Int J Clin Oncol 14 2009 490 496
109. M. Kusano, Y. Tajima, K. Yamazaki, M. Kato, M. Watanabe, and M. Miwa Sentinel node mapping guided by indocyanine green fluorescence imaging: a new method for sentinel node navigation surgery in gastrointestinal cancer Dig Surg 25 2008 103 108 (Pubitemid 351748763)
110. J.H. Winer, H.S. Choi, S.L. Gibbs-Strauss, Y. Ashitate, Y.L. Colson, and J.V. Frangioni Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared fluorescent light Ann Surg Oncol 17 2010 1094 1100
111. K. Gotoh, T. Yamada, and O. Ishikawa A novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation J Surg Oncol 100 2009 75 79
112. M. Keramidas, V. Josserand, C.A. Righini, C. Wenk, C. Faure, and J.L. Coll Intraoperative near-infrared image-guided surgery for peritoneal carcinomatosis in a preclinical experimental model Br J Surg 97 2010 737 743
113. R.A. Sheth, R. Upadhyay, L. Stangenberg, R. Sheth, R. Weissleder, and U. Mahmood Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model Gynecol Oncol 112 2009 616 622
114. T.F. Massoud, R. Paulmurugan, and S.S. Gambhir A molecularly engineered split reporter for imaging protein-protein interactions with positron emission tomography Nat Med 16 2010 921 926
115. A.D. Nunn The cost of developing imaging agents for routine clinical use Invest Radiol 41 2006 206 212 (Pubitemid 44406180)
116. W.A. Weber, J. Czernin, M.E. Phelps, and H.R. Herschman Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs Nat Clin Pract Oncol 5 2008 44 54 (Pubitemid 351512428)
117. G. Mills The exploratory IND J Nucl Med 49 2008 45N 47N
118. S. Vallabhajosula (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization Semin Nucl Med 37 2007 400 419 (Pubitemid 47505221)
119. A.F. Shields, J.R. Grierson, and B.M. Dohmen Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1998 1334 1336 (Pubitemid 28512118)
120. M.M. Graham The clinical trials network of the society of nuclear medicine Semin Nucl Med 40 2010 327 331